Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum
- 1 April 2014
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (7) , 1698-1701
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Health (GM56550, GM57144)
- the National Science Foundation (MCB-1157506)
This publication has 32 references indexed in Scilit:
- Development of Plasmodium falciparum Protease Inhibitors in the Past Decade (2002–2012)Current Medicinal Chemistry, 2013
- Recent Advances in Plasmepsin Medicinal Chemistry and Implications for Future Antimalarial Drug Discovery EffortsCurrent Topics in Medicinal Chemistry, 2012
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Plasmepsins as potential targets for new antimalarial therapyMedicinal Research Reviews, 2006
- The Role of Plasmodium falciparum Food Vacuole PlasmepsinsJournal of Biological Chemistry, 2005
- Search for substrate‐based inhibitors fitting the S2′ space of malarial aspartic protease plasmepsin IIJournal of Peptide Science, 2004
- High-Affinity Inhibition of a Family of Plasmodium falciparum Proteases by a Designed Adaptive InhibitorBiochemistry, 2003
- Identification and Characterization of Allophenylnorstatine-Based Inhibitors of Plasmepsin II, an Antimalarial TargetBiochemistry, 2002
- Four plasmepsins are active in thePlasmodium falciparumfood vacuole, including a protease with an active-site histidineProceedings of the National Academy of Sciences, 2002
- Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targetsTrends in Parasitology, 2001